- Dual antiplatelet therapy in patients after surgical revascularization of myocardium2014 | Faculty of Medicine in Hradec Králové
- Bioptically Proven "Anticoagulation-Related Nephropathy" Induced by Dual Antiplatelet Therapy2018 | Third Faculty of Medicine
- The DAPT trial: 12 or 30 months of dual antiplatelet therapy after implantation of drug-eluting stent2016 | First Faculty of Medicine
- Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents The Dual Antiplatelet Therapy Randomized Clinical Trial2015 | Publication without faculty affiliation
- Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease2020 | Central Library of Charles University
- Dual antiplatelet therapy - golden standard in high cardiovascular risk2010 | Third Faculty of Medicine
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents2014 | Faculty of Medicine in Hradec Králové
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology2017 | Third Faculty of Medicine
- Routine combination of dual antiplatelet therapy with proton pump inhibitors - are we not throwing the baby out with the bath water?2013 | First Faculty of Medicine, Third Faculty of Medicine
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention2016 | Publication without faculty affiliation
- The PRODIGY study: at last we know how to treat with clopidogrel after coronary angioplasty2011 | First Faculty of Medicine
- Antiplatelet therapy after BVS implantation2017 | First Faculty of Medicine
- Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease2013 | Third Faculty of Medicine
- Stent or balloon: How to treat proximal internal carotid artery occlusion in the acute phase of ischemic stroke? Results of a short survey2016 | Third Faculty of Medicine
- News in secondary prevention of atherothrombotic events - focus on ticagrelor2016 | First Faculty of Medicine
- Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Implantation in Patients Without Indications for Chronic Oral Anticoagulation: A systematic review and network meta-analysis of randomized controlled trials2023 | Third Faculty of Medicine
- High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis2009 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Antithrombotic therapy - not only for patients after peripheral arterial interventions2019 | First Faculty of Medicine
- Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry2014 | Third Faculty of Medicine
- Ticagrelor in Patients with Stable Coronary Disease and Diabetes2019 | Third Faculty of Medicine
- Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome2015 | Publication without faculty affiliation
- Tikagrelor v prolongaci protidestičkové medikace u nemocných po infarktu myokardu2019 | First Faculty of Medicine, Third Faculty of Medicine
- ESVM Guideline on peripheral arterial disease2019 | Third Faculty of Medicine
- Study CHARISMA2006 | First Faculty of Medicine
- Endoscopic treatment of a giant pedunculated angiolipofibroma of the distal duodenum2011 | Faculty of Medicine in Hradec Králové
- Antiplatelet therapy in acute coronary syndromes2010 | Publication without faculty affiliation
- Subacute thrombosis of two stents as a cause of acute myocardial infarction2009 | Third Faculty of Medicine
- Prasugrel or tikagrelor2013 | First Faculty of Medicine
- Antiplatelet therapy in patients with chronic anticoagulant therapy2019 | First Faculty of Medicine
- PIONEER AD-PCI trial: rivaroxaban in the therapy of atrial fibrillation patients undergoing percutaneous coronary intervention2017 | Publication without faculty affiliation